Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain ventricle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Brain ventricle. Displaying page 1 of 1.
    EudraCT Number: 2017-005077-39 Sponsor Protocol Number: BBLOQ-2017 Start Date*: 2018-06-12
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Betablockers Withdrawal in Patients with Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence: Effect on Functional Capacity and life quality
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000797-30 Sponsor Protocol Number: SPI-IIT-002 Start Date*: 2013-10-08
    Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital
    Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation
    Medical condition: Paroxysmal and persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10071667 Persistent atrial fibrillation LLT
    18.1 100000004849 10066664 Recurrent symptomatic atrial fibrillation LLT
    18.1 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001306-87 Sponsor Protocol Number: CANc/CHF14/TIF Start Date*: 2005-06-13
    Sponsor Name:TAKEDA
    Full Title: EFFECTS OF CANDESARTAN CILEXETIL VS STANDARD THERAPY ON SERUM LEVELS OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS SUFFERING FROM CHRONIC HEART FAILURE WITH DEPRESSED AND PRESERVED SYSTOLIC FUNCTION
    Medical condition: CHRONIC HEART FAILURE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024120 Left ventricular failures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-004186-21 Sponsor Protocol Number: VICTORID_01 Start Date*: 2023-09-14
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Beneficial effects of vitamin D combined with oral iron supplementation in patients with chronic heart failure and iron deficiency (VICTORID-HF TRIAL)
    Medical condition: Chronic heart failure; iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019284 Heart failure, congestive LLT
    20.0 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    20.1 10007541 - Cardiac disorders 10064081 Heart failure NYHA class III LLT
    20.1 10007541 - Cardiac disorders 10064080 Heart failure NYHA class II LLT
    24.0 100000004861 10060496 Hyposideremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004207-22 Sponsor Protocol Number: CLCZ696B2319 Start Date*: 2017-04-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled s...
    Medical condition: Pediatric heart failure 1 month to <18 years old
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Ongoing) SE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) HU (Completed) HR (Completed) AT (Completed) PT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-022583-13 Sponsor Protocol Number: CRAD001MIC02 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everol...
    Medical condition: The study will evaluate the safety of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) CZ (Completed) FR (Ongoing) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004072-59 Sponsor Protocol Number: 1245-0167 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002645-38 Sponsor Protocol Number: BIOMARCHA Start Date*: 2012-09-04
    Sponsor Name:CRESIB-Barcelona Centre for International Health Research
    Full Title: Evolution of serologic biomarkers and diastolic function and segmentary contractility determined by echocardiography after treatment in Chagas diseases
    Medical condition: The study will be held in 63 patients with chronic Chagas Disease and 63 healthy people
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000298-65 Sponsor Protocol Number: BAY1021189/19334 Start Date*: 2018-06-11
    Sponsor Name:Bayer AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activi...
    Medical condition: Heart failure and preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) AT (Completed) ES (Completed) HU (Completed) BG (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001109-22 Sponsor Protocol Number: PBGM01-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Passage Bio, Inc.
    Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su...
    Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006997-27 Sponsor Protocol Number: CRAD001M2301 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)
    Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005093-19 Sponsor Protocol Number: AT251-G-17-005 Start Date*: 2019-01-08
    Sponsor Name:Akros Pharma Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JTT-251 Administered for 24 Weeks to Participants with Heart Failure with Reduced E...
    Medical condition: Heart Failure with Reduced Ejection Fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002400-20 Sponsor Protocol Number: 81866 Start Date*: 2023-02-28
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Feasibility of empagliflozin as treatment for idiopathic pulmonary arterial hypertension
    Medical condition: Idiopathic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018863-40 Sponsor Protocol Number: BAY63-2521/15096 Start Date*: 2010-07-16
    Sponsor Name:Bayer HealthCare AG
    Full Title: An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretre...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002554-21 Sponsor Protocol Number: 251PP301 Start Date*: 2017-07-21
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy
    Medical condition: Progressive supranuclear palsy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Prematurely Ended) GR (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006916-39 Sponsor Protocol Number: IVH06 Start Date*: 2009-07-23
    Sponsor Name:Johns Hopkins University
    Full Title: Clot lysis: evaluating accelerated resolution of intraventricular hemorrhage Phase III
    Medical condition: Intraventricular haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10022840 Intraventricular haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000379-32 Sponsor Protocol Number: D4200C0007A Start Date*: 2004-09-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untrea...
    Medical condition: Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004073-14 Sponsor Protocol Number: 1245-0168 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with reduced Ejection Fraction (HFrEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:59:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA